(Calcium carbonate + lansoprazole) is under clinical development by Addpharma and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase I drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Calcium carbonate + lansoprazole)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Calcium carbonate + lansoprazole) overview

AD-212-A is under development for the treatment of gastro esophageal reflux disease. The drug candidate is a combination of lansoprazole and calcium carbonate. It is administered through oral route as a tablet.

Addpharma overview

Addpharma is a specialized pharmaceutical company that develops medicinal novel drugs including complexes, release controlling agents, and absorption improving agents. Addpharma is headquartered in Yongin, South Korea.

For a complete picture of (Calcium carbonate + lansoprazole)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.